MorphoSys (ETR:MOR) received a €98.00 ($120.99) price target from equities researchers at Commerzbank in a research report issued to clients and investors on Monday. The brokerage currently has a “buy” rating on the stock. Commerzbank’s target price suggests a potential upside of 13.56% from the stock’s previous close.
Other equities research analysts also recently issued research reports about the company. Oddo Bhf set a €90.00 ($111.11) price objective on MorphoSys and gave the company a “buy” rating in a report on Tuesday, February 20th. JPMorgan Chase & Co. reiterated a “buy” rating and issued a price objective on shares of MorphoSys in a report on Tuesday, March 13th. Deutsche Bank set a €94.00 ($116.05) price objective on MorphoSys and gave the company a “buy” rating in a report on Monday, March 12th. Berenberg Bank set a €85.00 ($104.94) price target on MorphoSys and gave the stock a “buy” rating in a report on Thursday, December 7th. Finally, Independent Research set a €93.00 ($114.81) price target on MorphoSys and gave the stock a “buy” rating in a report on Friday, December 1st. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the stock. MorphoSys currently has an average rating of “Hold” and a consensus price target of €84.02 ($103.73).
Shares of MorphoSys stock opened at €86.30 ($106.54) on Monday. The company has a market capitalization of $2,490.00 and a PE ratio of -35.81. MorphoSys has a fifty-two week low of €49.63 ($61.27) and a fifty-two week high of €88.10 ($108.77).
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.